Skip to main content




earned $197 million, or 15 cents a share, from continuing operations in its fourth quarter on a 10% increase in pharmaceuticals sales.

Scroll to Continue

TheStreet Recommends

The company, which is reporting


agricultural operations as a discontinued operations, said it earned an adjusted $476 million, or 36 cents a share, in the quarter, matching analysts' forecasts.

Pharmacia reported strong results for several of its main drugs, including arthritis treatment Celebrex, which posted a 17% increase in fourth-quarter sales to $904 million, and glaucoma treatment Xalatan, which posted a 15% increase in fourth-quarter sales to $226 million.

Overall net sales for the company's pharmaceutical businesses were $3.7 billion in the fourth quarter, a 10% increase over the fourth quarter of 2000, or 12% excluding the impact of foreign exchange.